---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004700"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:16:03.368863+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences reports FY2023 revenue of $8.7M, down 22.8% as GLP-1 drugs pressure bariatric market

## Summary
- FY2023 revenue $8.7M, down 22.8% YoY; Lap-Band unit sales fell 26.8% due to GLP-1 competition.
- Gross profit $5.5M (63.9% margin vs 60.5% in 2022); sales & marketing expenses cut 46.8% to $7.5M.
- Cash $4.5M and debt-free; expects 2024 operating expenses to decrease >50% vs 2023 via further RIF.
- Received FDA approval for Lap-Band 2.0 FLEX in Dec 2023; first surgeries completed in Feb 2024.

## SEC filing metadata
- accession: 0001558370-24-004700
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/0001558370-24-004700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/rsls-20240401x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004700
- JSON: https://secwatch.observer/filing/0001558370-24-004700.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004700.txt

## Key facts
- Earnings Releases
  Vyome Holdings, Inc reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8.7 million. Guidance reaffirmed.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Revenue: $8.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue totaled $8.7 million for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/0001558370-24-004700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.